Ticagrelor is a platelet P2Y12 receptor inhibitor approved for use in patients with acute
coronary syndromes, coronary artery disease, and low‐moderate risk acute ischemic stroke …

Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the
therapy of atherothrombotic conditions due to their superiority over a standard combination …

Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic
cardiac complications in patients with acute coronary syndrome. Treatment guidelines for …

Importance of the field: High platelet reactivity has been linked to recurrent ischemic events
in patients treated with conventional dual antiplatelet therapy, in patients with arterial …

Introduction: Ticagrelor is a novel, non-thienopyridine ADP inhibitor that reversibly blocks
the P2Y12 receptor, preventing platelet activation and aggregation. It is the first ADP …

Platelets participate centrally in atherothrombosis, resulting in vessel occlusion and
ischaemia. Consequently, optimisation of antiplatelet regimens has the potential to further …

Ticagrelor is a reversible P2Y12 receptor antagonist that is more potent than clopidogrel.
When used in combination with aspirin, it reduces cardiovascular events in patients with …

Abstract Ticagrelor (Brilique™; Brilinta™), a cyclopentyl-triazolo-pyrimidine antiplatelet
agent, is the first oral antagonist of the P2Y 12 receptor to offer reversible receptor binding. It …

Large outcome trials demonstrated various effects of antithrombotic strategies including
ticagrelor on clinical outcomes across patient populations. Pharmacokinetic …

Objective: To summarize the pharmacokinetic and pharmacodynamic properties of
ticagrelor, a selective P2Y12 receptor antagonist, and evaluate its role in the treatment of …